secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001437749-22-026900
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports Q3 2022 net loss of $22.3M for nine months; cash $50.4M sufficient beyond mid-2024
--------------------------------------------------------------------------------

- R&D expense $14.8M (nine months) vs $11.2M YoY; net loss $22.3M vs $13.1M.
- Cash $50.4M, sufficient beyond mid-2024; operating cash burn $20.4M.
- Three Phase 1/2 trials for Annamycin active; no cardiotoxicity in 42 subjects.
- WP1066 pediatric brain tumor trial enrolled final subject in Phase 1 at 8 mg/kg.
- WP1122 received FDA Orphan Drug for GBM; Phase 1a completed; WP1096 selected for NIH studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/0001437749-22-026900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/mbrx20221107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer